# Ascendis Pharma (ASND) — Earnings

ASND · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/asnd/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $3.23 |
| EPS estimate | $1.74 |
| EPS surprise | +85.97% |
| Revenue surprise | +2.54% |
| Revenue | $387.5M |
| Revenue estimate | $377.9M |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1612042/000119312526348046/d31437d6k.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/c94e7dec-3c53-824b-a305-1a9c0e1f95ac.html) |

Ascendis Pharma reported Q2 2026 results on August 13, 2026. Earnings per share were $3.23, beating the $1.74 estimate by 85.97%. Revenue of $387.5 million topped the $377.9 million consensus by 2.54%. In Q2 2025, Ascendis posted a loss of $0.97 per share on $186.2 million of revenue, so revenue roughly doubled year over year.

The table shows a long run of losses that ended this year. Ascendis lost money in all 18 quarters from Q3 2021 through Q4 2025. Annual losses per share narrowed from $10.98 in 2022 to $9.05 in 2023, $7.11 in 2024 and $4.50 in 2025. Revenue rose from about $54 million in 2022 to about $837 million in 2025. Q1 2026 stands apart, with EPS of $11.26 against a $0.21 estimate, far above any other quarter here. The first half of 2026 totals $14.49 per share. Ascendis beat the EPS estimate in 10 of the last 20 quarters.

Ascendis reported Q3 between November 2 and November 14 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether the company stays profitable.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | $1.74 | $3.23 | 85.97% | $377.9M | $387.5M |
| Q1 2026 | May 7, 2026 | $0.21 | $11.26 | 5241.35% | $309.0M | $284.9M |
| Q4 2025 | Feb 11, 2026 | −$0.22 | −$0.65 | -187.62% | $288.4M | $290.7M |
| Q3 2025 | Nov 12, 2025 | −$0.29 | −$1.17 | -309.56% | $250.2M | $250.7M |
| Q2 2025 | Aug 7, 2025 | −$1.51 | −$0.97 | 36.23% | $169.6M | $186.2M |
| Q1 2025 | May 1, 2025 | −$1.59 | −$1.71 | -7.68% | $102.6M | $109.2M |
| Q4 2024 | Feb 12, 2025 | −$1.02 | −$0.66 | 35.00% | $123.9M | $180.0M |
| Q3 2024 | Nov 14, 2024 | −$1.74 | −$1.92 | -9.92% | $78.3M | $64.4M |
| Q2 2024 | Sep 3, 2024 | −$1.56 | −$2.05 | -30.96% | $88.9M | $38.6M |
| Q1 2024 | May 2, 2024 | −$1.59 | −$2.48 | -55.73% | $85.8M | $103.5M |
| Q4 2023 | Feb 7, 2024 | −$2.00 | −$1.70 | 15.13% | $103.1M | $152.0M |
| Q3 2023 | Nov 7, 2023 | −$2.51 | −$2.84 | -13.37% | $51.7M | $47.4M |
| Q2 2023 | Sep 5, 2023 | −$2.75 | −$2.36 | 14.38% | $40.6M | $51.7M |
| Q1 2023 | Apr 27, 2023 | −$2.88 | −$2.15 | 25.50% | $23.4M | $36.4M |
| Q4 2022 | Feb 16, 2023 | −$2.84 | −$3.96 | -39.64% | $20.6M | $24.1M |
| Q3 2022 | Nov 2, 2022 | −$2.49 | −$3.04 | -22.10% | $8.6M | $15.4M |
| Q2 2022 | Aug 10, 2022 | −$2.27 | −$1.53 | 32.52% | $5.9M | $6.5M |
| Q1 2022 | May 11, 2022 | −$2.28 | −$2.45 | -7.39% | $5.0M | $7.6M |
| Q4 2021 | Mar 2, 2022 | −$2.62 | −$2.11 | 19.24% | $3.1M | $5.6M |
| Q3 2021 | Nov 10, 2021 | −$2.67 | −$1.70 | 36.26% | $1.3M | $1.3M |

## Frequently Asked Questions

### When did Ascendis Pharma (ASND) last report earnings?

Ascendis Pharma last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did ASND beat earnings estimates?

Yes. Ascendis Pharma reported EPS of $3.23 for Q2 2026 against a $1.74 estimate — a 85.97% beat.

### How much revenue did ASND report last quarter?

Ascendis Pharma reported $387.5M in revenue for Q2 2026, against a consensus estimate of $377.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).